A Dose-Ranging Study to Evaluate Fasting and Postprandial P-Glucose, Safety and Tolerability After Oral Single, B.I.D [bidaily] and Q.I.D [once daily] Dosing of AZD6370 in Patients With Diabetes Mellitus: a Randomized, Single-Blind, Placebo-Controlled, Phase I Study.

Trial Profile

A Dose-Ranging Study to Evaluate Fasting and Postprandial P-Glucose, Safety and Tolerability After Oral Single, B.I.D [bidaily] and Q.I.D [once daily] Dosing of AZD6370 in Patients With Diabetes Mellitus: a Randomized, Single-Blind, Placebo-Controlled, Phase I Study.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2012

At a glance

  • Drugs AZD 6370 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jan 2012 Last checked against ClinicalTrials.gov record.
    • 02 Dec 2010 Actual initiation date changed from (Oct 2007) to (Feb 2008) as reported by ClinicalTrials.gov.
    • 28 Jun 2008 The expected completion date for this trial is now 1 Jun 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top